Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;65(8):e263-e265.
doi: 10.1111/ajd.14372. Epub 2024 Oct 21.

Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single-centre study on 485 patients

Gabriele Perego  1 , Italo Francesco Aromolo  1 , Francesca Barei  2 , Martina Zussino  2 , Luca Valtellini  1 , Angelo Valerio Marzano  1   2 , Silvia Mariel Ferrucci  2
Affiliations

Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single-centre study on 485 patients

Gabriele Perego et al. Australas J Dermatol. 2024 Dec.
No abstract available

Keywords: atopic dermatitis; dermatological therapy; dupilumab; hands; quality of life.

PubMed Disclaimer

Conflict of interest statement

SM Ferrucci is principal investigator in clinical trial to Amgen, Sanofi, Novartis, Lilly, Leo Pharma, Abbvie and she is advisory board or speaker to Novartis, Menarini, Sanofi, Abbvie and Leo Pharma. The other authors declare that there is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
During treatment with dupilumab in AD, hands involvement at different follow‐up times, classified as persistent AD, intermittent AD and complete remission in that area. Patients were classified as follows: Persistent AD (if the hands remained consistently affected), intermittent AD (if the area alternated between periods of involvement and remission in the previous follow‐up visits) and clinical remission (if the area experienced complete persistent complete remission after the initial clearance). Not all patients were followed up for 3 years, as they were enrolled at different times. AD, atopic dermatitis; MX, follow‐up after X months (e.g. M4, at 4 months of follow‐up); n, number of patients evaluated at each follow‐up. Data not written in Figure 1: Patients with persistent AD are 1.8% at M24, 1.7% at M28, 0.5% at M32 and 0.6% at M36.
See this image and copyright information in PMC

References

    1. Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. Dermatitis. 2006;17(3):123–127. 10.2310/6620.2006.06005 - DOI - PubMed
    1. Fartasch M, Taeger D, Broding HC, Schöneweis S, Gellert B, Pohrt U, et al. Evidence of increased skin irritation after wet work: impact of water exposure and occlusion. Contact Dermatitis. 2012;67(4):217–228. 10.1111/j.1600-0536.2012.02063.x - DOI - PubMed
    1. Silverberg JI, Simpson B, Abuabara K, Guttman‐Yassky E, Calimlim B, Wegzyn C, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET‐DERM AD cohort. J Am Acad Dermatol. 2023;89(3):519–528. 10.1016/j.jaad.2023.04.052 - DOI - PubMed
    1. Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head‐and‐neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046–1055. 10.1111/jdv.18849 - DOI - PubMed
    1. Lee H, Kim BR, Kim KH, Lee DH, Na JI. One‐year effectiveness and safety of dupilumab treatment for moderate‐to‐severe atopic dermatitis in Korean patients: a real‐world retrospective analysis. Allergy, Asthma & Immunology Research. 2022;14(1):117–122. 10.4168/aair.2022.14.1.117 - DOI - PMC - PubMed